Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Avelumab con acido valproico nel cancro associato al virus (LATENT)

2 novembre 2026 aggiornato da: AHS Cancer Control Alberta

Lo studio LATENT: attivazione litica per potenziare la terapia mirata al neoantigene Uno studio per valutare la fattibilità e l'efficacia dell'uso combinato di Avelumab con acido valproico per il trattamento del cancro associato al virus

Up to 20% of all cancers may be associated with a bacterial or viral infection. In some instances, the infection may be one of the reasons why the cancer developed in the first place. One such example is infection with the human papilloma virus (HPV) and the development of cervical or oral cavity cancer.

A viral infection that is chronic may not cause a person symptoms, and may be able to escape detection by a person's own immune system. One of the medications being studied in this clinical trial (Valproic acid) may be able to unmask a chronic viral infection from a person's own immune system, therefore making the virus susceptible to attack by the immune system. In this study Valproic acid is being combined with an immune therapy, Avelumab. Avelumab is an antibody that targets a person's own immune cells, or lymphocytes. Lymphocytes must be activated to fight infections or cancer, but after activation they are deactivated. Avelumab prevents the deactivation of a lymphocyte, in effect "turning off the off-switch." This leads to a re-energizing of a person's immune system, hopefully leading to an attack by the immune system on a person's cancer.

Avelumab is known to be an effective treatment for a variety of cancers, although it has not yet been tested in all cancers. By combining Valproic acid, a treatment which targets the virus that contributed to the development of this type of cancer with Avelumab the investigators hope to enhance the ability of Avelumab to restore the body's own immune defense against the cancer.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

39

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Cross Cancer Institute

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Patients must be 18 years of age or older.

  • Patients with the following histologically confirmed diagnoses will be eligible for enrolment: p16 positive SCCHN; squamous cell carcinoma of the cervix; p16 positive squamous cell carcinoma of the vagina or vulva; p16 positive squamous cell carcinoma of the penis; p16 positive squamous cell carcinoma of the anus or anal canal; EBER positive NPC; EBER positive Hodgkins and non-hodgkins lymphoma.

  • Note: patients with p16 positive SCC of unknown primary origin meeting the minimum life expectancy and performance status requirements will also be eligible for enrollment, as the majority of these patients may be assumed to represent HPV-associated disease.

  • Patients must be capable of providing consent to enrolment and treatment.

  • Patients with a performance status of ECOG 0-1(51) will be eligible for enrolment (see appendix 1).

  • Measurable disease must be present according to irRECIST criteria(50).

  • Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test at the time of screening.

  • Patients of childbearing / reproductive potential should use highly effective birth control methods, as defined by the investigator, during the study treatment period and for a period of 60 days after the last dose of study drug. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.

  • Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.

  • Female patients who are breast-feeding should discontinue nursing prior to the first dose of study treatment and until 120 days after the last dose of study drug.

  • Absence of any condition hampering compliance with the study protocol and follow- up schedule; those conditions should be discussed with the patient before registration in the trial.

  • The following adequate organ function laboratory values must be met:

  • Hematological:

    • Absolute neutrophil count (ANC) >1.5 x109/L
    • Platelet count >100 x109/L
    • Hemoglobin >9 g/dL (may have been transfused)
  • Renal:

    o Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method)

  • Hepatic:

    • Total serum bilirubin <1.5x ULN
    • AST and ALT <2.5x ULN (or ≤ 5 x ULN for subjects with documented metastatic disease to the liver)
    • Serum albumin > 25 g/L
  • Coagulation:

    • International Normalized Ratio (INR) <1.5x ULN (unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants)
    • Activated Partial Thromboplastin Time (aPTT) <1.5x ULN (unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants)

Exclusion Criteria:

  • History of pneumonitis requiring treatment with steroids.
  • History of interstitial lung disease.
  • Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
  • History of another malignancy or a concurrent malignancy;
  • Exceptions include patients who have been disease-free for 5 years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ.
  • Active brain metastases or leptomeningeal disease.
  • Patients with treated brain metastases that are stable for 6 weeks will be eligible for enrolment.
  • Diagnosis of immunodeficiency.
  • Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
  • Prior organ transplantation including allogenic stem-cell transplantation.
  • Known history of human immunodeficiency virus (HIV).
  • Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).
  • Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
  • Patients with hyperthyroidism or hypothyroidism but that are stable on hormone replacement will not be excluded.
  • Active infection requiring systemic therapy.
  • Vaccination within 4 weeks of the first dose of Avelumab and while on trials is prohibited except for administration of inactivated vaccines.
  • Patient will not be eligible if the patient is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific subject.
  • Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.
  • Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade ≥ 3).
  • Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Avelumab with VPA

Valproic Acid (VPA, 12.5 mg/kg) once per day and Avelumab (10 mg/kg IV) every 2 weeks for up to 2 years.

The target serum level for VPA will be between 75 and 100 mcg/mL checked every 2 weeks for the first 6 cycles.

10 mg/kg IV

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Efficacy of Avelumab and VPA
Lasso di tempo: 1 year after enrolment of last patient

• Assessment of the clinical response rate according to the immune-related RECIST criteria (iRECIST)

1 year after enrolment of last patient
Proportion of subjects who complete 4 doses of Avelumab in combination with VPA
Lasso di tempo: 1 year after enrolment of last patient

• Feasibility analysis, defined as the proportion of subjects who complete 4 doses of Avelumab in combination with VPA over the total duration of the study.

1 year after enrolment of last patient

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Identificare tumori specifici associati a virus come candidati per studi successivi
Lasso di tempo: Attraverso il completamento degli studi, fino a 2 anni
Attraverso il completamento degli studi, fino a 2 anni
Misurazione dell'espressione MHC
Lasso di tempo: Attraverso il completamento degli studi, fino a 2 anni
Attraverso il completamento degli studi, fino a 2 anni
Misurazione del DNA tumorale libero nel sangue
Lasso di tempo: Attraverso il completamento degli studi, fino a 2 anni
Attraverso il completamento degli studi, fino a 2 anni
Fenotipizzazione dei linfociti infiltranti il ​​tumore
Lasso di tempo: Attraverso il completamento degli studi, fino a 2 anni
Attraverso il completamento degli studi, fino a 2 anni
Espressione di geni virali litici
Lasso di tempo: Attraverso il completamento degli studi, fino a 2 anni
Attraverso il completamento degli studi, fino a 2 anni
Immunofenotipizzazione dei linfociti T citotossici
Lasso di tempo: Attraverso il completamento degli studi, fino a 2 anni
Attraverso il completamento degli studi, fino a 2 anni
Sequenziamento del recettore delle cellule T
Lasso di tempo: Attraverso il completamento degli studi, fino a 2 anni
Attraverso il completamento degli studi, fino a 2 anni
Concentrazione di Hsp90 nel siero
Lasso di tempo: Attraverso il completamento degli studi, fino a 2 anni
Attraverso il completamento degli studi, fino a 2 anni
Overall survival
Lasso di tempo: 5 years from final study drug dose

defined as the time from the date of enrollment to the date of death, whatever the cause.

5 years from final study drug dose
Progression free survival
Lasso di tempo: 5 years from final study drug dose

Progression free survival is defined as the time between the date of treatment initiation and the date of disease progression or death (whatever the cause), whichever occurs first.

5 years from final study drug dose
Number of participants with adverse events
Lasso di tempo: Through study completion, up to 2 years

• Incidence of adverse events (assessed as the incidence and severity of adverse events, including immune-related adverse events, and the number of discontinuations due to adverse events).

Through study completion, up to 2 years
Measurement of Immuno-score
Lasso di tempo: Through study completion, up to 2 years

AffymetriX Micro-array (Immuno-score)

Through study completion, up to 2 years
DNA viral load
Lasso di tempo: Through study completion, up to 2 years

DNA Quantitative PCR (viral load)

Through study completion, up to 2 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: John Walker, MD PhD FRCPC, Alberta Health services

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

7 febbraio 2018

Completamento primario (Effettivo)

30 marzo 2022

Completamento dello studio (Effettivo)

31 marzo 2025

Date di iscrizione allo studio

Primo inviato

16 novembre 2017

Primo inviato che soddisfa i criteri di controllo qualità

24 novembre 2017

Primo Inserito (Effettivo)

30 novembre 2017

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

4 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • LATENT

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .